TARSA THERAPEUTICS
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
TARSA THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Medical Device
Founded:
2009-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.tarsatherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
267-273-7940
Total Funding:
124.25 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon WordPress Google Analytics SSL By Default HSTS Organization Schema Sitelinks Search Box
Similar Organizations
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
CONMED
CONMED Corporation is a global medical technology company that specializes in the development.
Evernow
Evernow is a provider of women's health care services before, during, and after menopause.
Genecis
Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into high value materials.
HAYA Therapeutics
HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.
Impulse Dynamics
Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF).
Neuro42
Neuro42 is developing and commercializing advanced MRI technology for diagnosis and image-guided interventions.
Vertos Medical
Vertos Medical is a healthcare company that develops and markets medical devices that are used for the treatment of common spinal diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Square 1 Bank
Square 1 Bank investment in Debt Financing - Tarsa Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Tarsa Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Tarsa Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Tarsa Therapeutics
Quaker Partners
Quaker Partners investment in Series B - Tarsa Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Series B - Tarsa Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Tarsa Therapeutics
MVM Life Science Partners
MVM Life Science Partners investment in Series B - Tarsa Therapeutics
Marker
Marker investment in Series B - Tarsa Therapeutics
Quaker BioVentures
Quaker BioVentures investment in Series B - Tarsa Therapeutics
Official Site Inspections
http://www.tarsatherapeutics.com
- Host name: redirect-v225.secureserver.net
- IP address: 184.168.47.225
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Tarsa Therapeutics"
Tarsa Therapeutics - Crunchbase Company Profile
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.See details»
Tarsa Therapeutics Company Profile | Management and ... - Datanyze
Tarsa Therapeutics Profile and History . Tarsa Therapeutics is a venture-backed clinical stage biotechnology company developing OSTORA™, an oral formulation of calcitonin for the …See details»
Tarsa Therapeutics Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, investors, and executives for Tarsa Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Tarsa Therapeutics, Inc. Company Profile | Philadelphia, PA ...
Find company research, competitor information, contact details & financial data for Tarsa Therapeutics, Inc. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
Tarsa Therapeutics - Products, Competitors, Financials, Employees ...
Nov 8, 2022 Headquarters Location. 8 Penn Center 1628 JFK Blvd Suite 1400. Philadelphia, Pennsylvania, 19103, United States. 267-273-7940See details»
Tarsa Therapeutics - Craft
Tarsa Therapeutics $95.6 m in total funding,. See insights on Tarsa Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Tarsa Therapeutics - VentureRadar
Similar Companies: Radius Health, Inc. USA Publicly Traded Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing …See details»
Tarsa Therapeutics Secures $10 Million and Adds Industry Veteran …
Sep 10, 2018 PHILADELPHIA, PA – August 13, 2014 — Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and …See details»
Tarsa Therapeutics Completes $28 Million Series B Financing to …
Sep 10, 2018 PHILADELPHIA, PA – March 16, 2012 — Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite …See details»
TARSA Therapeutics' NDA For TBRIA™, The First Oral Calcitonin …
Oct 19, 2015 For more information, visit www.tarsatherapeutics.com. Contact: BLL Partners, LLC Barbara Lindheim 212 584-2276 [email protected] SOURCE TARSA Therapeutics, Inc. …See details»
Tarsa Therapeutics' Drug Successful in Prevention of Post
Oct 16, 2012 This product has the potential to be the first approved oral calcitonin, a natural hormone with a long history of safety and efficacy as an osteoporosis therapy. Tarsa is based …See details»
Tarsa Therapeutics Raises $7 Million to Prepare for Filing NDA for ...
May 29, 2014 Recently Revised Label for Marketed Calcitonin Products Has Helped Clarify the Regulatory Landscape in the U.S. Industry Veteran Nicholas LaBella Joins Tarsa as Vice …See details»
Tarsa Therapeutics Advances Phase III ORACAL Trial of its Oral ...
Jul 22, 2010 Tarsa Therapeutics is developing an oral formulation of calcitonin for the treatment of osteoporosis. Calcitonin is a peptide hormone that inhibits bone resorption, the underlying …See details»
Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin …
Feb 14, 2011 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant...See details»
Tarsa Therapeutics Advances Its Oral Calcitonin for the Treatment …
Jul 12, 2011 Completes Patient Enrollment in Phase II Osteoporosis Prevention Trial Will Present Full Data Set on Phase III ORACAL Treatment Trial at ASBMR Closes Additional …See details»
Tarsa Therapeutics Advances Phase III ORACAL Trial of its Oral ...
PHILADELPHIA, July 22 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal …See details»
Tarsa Therapeutics Advances Phase III ORACAL Trial of its Oral ...
PHILADELPHIA, July 22. /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal …See details»
Tarsa Therapeutics’ NDA for TBRIA(TM), the First Oral Calcitonin …
Oct 19, 2015 Need for Safe and Effective New Therapies Highlighted by Limited Existing Treatment Options and Large Population of Underserved Osteoporosis Patients …See details»
News Archives - Tarsa Therapeutics
Tarsa Therapeutics’ NDA for TBRIA(TM), the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis, Accepted for Filing mkulwiec 2018-09-10T00:00:49+00:00See details»